XML 52 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Description of Business (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Impact of Change in Reporting Entity on Unaudited Consolidated Statements of Operations
The following table provides the impact of the change in reporting entity on our unaudited condensed consolidated statement of operations for the three months ended March 31, 2021 (in thousands):
Three Months Ended
March 31, 2021
(Unaudited)
NantCellNantKwestIntercompany
Eliminations		ImmunityBio,
Inc.
Revenue$183 $— $(44)$139 
Operating expenses:
Research and development (including amounts
with related parties)		21,509 19,725 (106)41,128 
Selling, general and administrative (including amounts
with related parties)		24,382 20,903 (10)45,275 
Loss from operations(45,708)(40,628)72 (86,264)
Other (expense) income, net (including amounts
with related parties)		(848)6,637 — 5,789 
Income tax expense— (6)— (6)
Net loss$(46,556)$(33,997)$72 $(80,481)